Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

1,106

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

October 31, 2013

Conditions
DiphtheriaTetanusWhooping CoughHepatitis BPoliomyelitis
Interventions
BIOLOGICAL

DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide

0.5 mL, Intramuscular each into the right and left deltoid muscle

BIOLOGICAL

DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide

0.5 mL, Intramuscular each into the right and left deltoid muscle

BIOLOGICAL

DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine

0.5 mL (each), Intramuscular each into the right and left deltoid muscle

Trial Locations (2)

Unknown

Santiago de Cali

San José

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01444781 - Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants | Biotech Hunter | Biotech Hunter